Islandsbanki hf. : 1Q 2017 Interim Financial Statements

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
67
Islandsbanki hf. : 1Q 2017 Interim Financial Statements

Íslandsbanki's Condensed Consolidated Interim Financial Statements

Highlights in 1Q 2017:

  • Earnings from regular operations was ISK 3.5bn, which is at comparable levels to1Q16.
  • Return on equity from regular operations on 15% CET1 was 10.6% in 1Q17 compared to 9.4% in 1Q16.
  • Profit after tax was ISK 3.0bn in 1Q17, compared to ISK 3.5bn in 1Q16. The profit in 1Q17 was driven by strong core income. Return on equity was 7.0% in 1Q17, compared to 6.9% in 1Q16.
  • Net interest income amounted to ISK 7.4bn in 1Q17 (1Q16 ISK 7.5bn) down 2% over the year. The net interest margin was 2.9% in 1Q17 (1Q16: 2.9%).
  • Net fee and commission income was ISK 3.3bn in 1Q17 compared to 3.1bn in 1Q16, up 4% over the year.
  • Administrative costs totalled ISK 6.4bn in 1Q17, down 1.5% from 1Q16.
  • Cost to income ratio was 60.1% in 1Q17 (1Q16: 59.0%), the cost to income ratio excludes the bank tax and one-off cost items.
  • Total assets amounted to ISK 1,029bn (Dec16: ISK 1,048bn), whereby loans to customers and liquidity portfolio account for 96% of the balance sheet.
  • Loans to customers grew by 2.3% (ISK 15.7bn) in 1Q17 to ISK 703bn. Total new lending was ISK 46bn across various lending divisions.
  • Asset quality continues to improve whereby the ratio of loans more than 90 days past due and impaired continues to improve and was 1.6% (Dec16: 1.8%).
  • Deposits from customers contracted by 4.5% (ISK 27bn) in 1Q17 to ISK 567bn.
  • Total capital ratio was 23.1% and CET1 ratio was 22.8% at period end, compared to 25.2% and 24.9% respectively at year-end 2016.
  • The liquidity position is strong and exceeds internal and external requirements. At period end the Bank's liquidity coverage ratio (LCR) was 181% (Dec16: 187%) and the total net stable funding ratio (NSFR) was 121% (Dec16: 123%).
  • Leverage ratio was 15.5% at  Mar17 compared to 16.0% at Dec16, indicating a moderate leverage.
  • Íslandsbanki is the only Icelandic bank to have two international credit ratings. In January 2017, Fitch upgraded the Bank to BBB/F3, with a stable outlook, and in October 2016, S&P upgraded the Bank to BBB/A-2, with a positive outlook.

Birna Einarsdóttir, Chief Executive Officer:

"Our core operations continued to produce stable core income, whereby net interest income and net fee and commission income contributed to 97% of the Bank's total income. Return on equity from regular operations on 15% CET1 was 10.6%, compared to 9.4% in 1Q16. In March, the AGM approved a dividend payment of ISK 10bn to the Bank's shareholders for 2016 profits. All liquidity and capital measures remain solid and leverage remains modest at 15.5%.

The full capital account liberalisation introduced in March marks a significant milestone for the Icelandic economy. As a result, upgrades were granted to the Iceland sovereign ratings. Íslandsbanki also received an upgrade and now has a BBB rating from both Fitch and S&P.

This step towards a more normalised operating environment in Iceland is a gratifying one for Íslandsbanki. Over the quarter, ISK 46bn was granted in new lending which was well spread across all business segments. Net fee and commission income was up 4% over the year. Corporate finance has been very active and closed several mandates. We also note a rise in demand for interest rate and FX risk related products from both domestic and international customers.

Individuals and companies are now allowed to invest in international securities without limitations. VÍB, Íslandsbanki's wealth management arm, has a broad range of funds available to clients that only invest in international markets. Customers can now also buy foreign currency in the online bank and process payments to overseas accounts as per usual.

In April, the branches in Kirkjusandur and Suðurlandsbraut were merged to form Laugardalur, the Bank's largest branch for individuals and SMEs. As a result, Íslandsbanki continues to operate the most efficient branch network in Iceland, with 14 branches nationwide. Simultaneously, we are making great strides in digitalisation and customer satisfaction continues to rise. For four years in a row, Íslandsbanki has been named Iceland's #1 bank in the Icelandic Customer Satisfaction Survey."

Investor call in English

The Bank will also host an investor call in English to present the results at 1 pm Icelandic time. The call will start with a short macro update on the Icelandic economy, followed by a review of the financial results and Q&A. Please register by replying to ir@islandsbanki.is . Dial-in details and presentation will be sent out two hours prior to the call.

All presentation material will subsequently be available and archived on www.islandsbanki.is/ir.

For information on Íslandsbanki's financial calendar and silent periods see http://www.islandsbanki.is/english/investor-r.../calendar/ .

 

For further information:

Investor Relations - Tinna Molphy, tinna.molphy@islandsbanki.is , tel +354 440 3187.

Media Relations - Edda Hermannsdottir, edda.hermannsdottir@islandsbanki.is and tel: +354 440 4005.

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...80896507c9

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...d00f21aac1

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...2289284c35

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...9e623a8c75

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...6a80c76f5f

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Valmet Expands Board Maker Deal in Asia With New Line

Updated Category News Views 87

If there's one thing Valmet understands, it's the beauty of a longstanding business relationship. On November 9, 2026, the Finnish powerhouse announced another feather in its cap—a new board making line order from a major client in Asia. This deal ain't just another tick in the order books. No, sir, it's about prowess and power in the paper game. Building on Existing...

Continue Reading
O-I Glass Faces Class Action: Investor Implications

Updated Category News Views 68

O-I Glass in Hot Water Over Misleading Statements I'll tell you, nothing gets my goat quite like uncovering deceptive practices in the corporate world. It seems O-I Glass, Inc. (NYSE: OI), might have played a fast one with its shareholders. The company is staring down the barrel of a class action lawsuit from Schall, Brown & Schwartz LLP, alleging they weren't entirely...

Continue Reading
KT&G Launches Heated Tobacco in Kazakhstan's Market

Updated Category News Views 43

KT&G Lights Up Kazakhstan In a bold move, KT&G is laying down the gauntlet in Kazakhstan's tobacco market, introducing its cutting-edge heated tobacco gizmo and a handful of sleek FAIIM sticks. Launching this October, these aren't just any devices—they're the FLEX locals have been waiting for, rebranded from South Korea's lil AIBLE and AIIM but made to fit right in with...

Continue Reading
Xiaomi's Smart Auto Factory Draws Global Media Praise

Updated Category News Views 178

Xiaomi Impresses Global Media in Beijing Factory Tour In the ever-changing world of NEVs (New Energy Vehicles), a tour of Xiaomi's smart auto factory in Beijing has made waves among global media folks. These scribes got an up-close look at Xiaomi's magic mix of tech and style on November 6, part of a grand media gathering. What's Under the Hood? Marcos Costa de Oliveira,...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 730

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 323

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 226

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
Niagara Networks Boosts TLS 1.3 Decryption to 90+ Gbps

Updated Category News Views 73

In a digital era where encryption is racing ahead like a runaway train, Niagara Networks has stepped up with some serious muscle enhancements to their ePacketron platform. They're not just playing catch-up with the latest TLS 1.3 decryption capabilities; they're leading the charge with a robust over 90 Gbps performance—no small feat in today's encrypted traffic...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 490

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 228

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
aria-label="Continue reading: JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer"> Continue Reading